AZN vs. LLY: Which Stock Is the Better Value Option?
Positive results for Biogen's Alzheimer's disease candidate are boosting all three stocks.
The results of a key Alzheimer's drug trial on Wednesday have reignited decades-old hopes that targeting a particular protein helps arrest the progression of the fatal brain disease, giving a big boos

Here Are 25 Billion Reasons to Invest in Eli Lilly

09:53am, Wednesday, 28'th Sep 2022
The drugmaker is expertly planning for the future.
The news could be good for patients suffering from a debilitating disease.
Nvidia Corporation (NASDAQ: NVDA) is a “fallen angel” that continues to be a great pick for the long-term investors, according to Ankur Crawford – Portfolio Manager at Alger.
Shares of this well-established drugmaker could soar on the back of a new diabetes drug.
S&P 500 giant Eli Lilly leads five medical stocks setting up and showing relative strength in the ongoing bear market. The post S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market appeared fi
This segment originally aired on September 22, 2022. UBS analysts upgraded Eli Lilly stock to Buy, stating that the pharma company's Type 2 diabetes medication could become a best-selling drug.
Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the n
Many commentators, analysts, and economists are convinced that the U.S. will enter a recession next year. Given the strength of the labor market and of corporate balance sheets, along with the onshori
Colin Bristow, UBS analyst, joins 'Closing Bell' to discuss the excitement around Eli Lilly's new diabetes drug, what goes into the $25 billion estimate that UBS has for the new drug and the company's
The FDA grants approval to Lilly's (LLY) Retevmo in advanced or metastatic solid tumors with a RET gene fusion. It converts the drug's accelerated approval in NSCLC indication to full approval.
UBS Group (SWX: UBSG), a global financial provider, upgraded Eli Lilly (NYSE: LLY) to buy from neutral on Tuesday, September

Eli Lilly Stock Rises on FDA Approval, Upgrade

10:03am, Thursday, 22'nd Sep 2022
Eli Lilly and Co (NYSE:LLY) is getting a boost today, after news that the U.S. Food & Drug Administration (FDA) approved its cancer drug Retevmo for new uses, including treatment of patients with a
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE